

## SOUTH SUDAN

### Support for Inactivated Polio Virus Vaccine

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b>	South Sudan						
<b>2. Vaccine grant number:</b>	15-SDS-08h-Y, 1518-SDS-25b-X, 19-SDS-25b-X, 20-SDS-25b-X						
<b>3. Date of Decision Letter:</b>	9/30/2019						
<b>4. Date of the Partnership Framework Agreement:</b>	10 July 2013						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Inactivated Polio Virus, Routine						
<b>6. Vaccine type:</b>	Inactivated Polio Virus						
<b>7. Requested product presentation and formulation of vaccine:</b>	Inactivated Polio Vaccine, 5 doses per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2015-2020						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	<b>2015-2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	3,190,523	314,000	-	-	-	-	3,504,523
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2015	15-SDS-08h-Y					341,099
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	28 April, 2015						169,777
	04 June, 2015						171,322
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2015-2019</b>	<b>2020</b>					<b>2021</b>

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Number of vaccine doses		115,700	-										
Annual Amounts (US\$)	3,190,523	314,000	-										
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.												
<b>14. Self-procurement:</b>	Not applicable												
<b>15. Co-financing obligations:</b>	<p>Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>												
<b>16. Operational support for campaigns:</b>	Not applicable												
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</td> <td></td> </tr> <tr> <td> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul> </td> <td>31 March 2020</td> </tr> <tr> <td></td> <td>15 May 2020</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		<ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	31 March 2020		15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates												
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:													
<ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	31 March 2020												
	15 May 2020												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat												
<b>18. Financial clarifications:</b>	Not applicable												
<p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>													

**19. Other conditions:**

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

On behalf of Gavi



Thabani Maphosa,  
Managing Director, Country Programmes  
30 September 2019